Omeros (NASDAQ:OMER) Stock Rating Upgraded by Wall Street Zen

Omeros (NASDAQ:OMER) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other research firms also recently commented on OMER. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, January 27th. HC Wainwright raised their target price on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $13.44 on Friday. The stock has a market cap of $967.68 million, a price-to-earnings ratio of -26.88 and a beta of 2.53. The company has a 50 day moving average of $11.39 and a 200-day moving average of $10.45. Omeros has a one year low of $2.95 and a one year high of $17.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, beating the consensus estimate of ($0.55) by $3.69. Equities research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC increased its stake in Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after purchasing an additional 79,263 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Omeros in the fourth quarter valued at approximately $159,000. Invesco Ltd. lifted its stake in Omeros by 26.8% in the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock valued at $2,658,000 after buying an additional 32,707 shares in the last quarter. Virtus Investment Advisers LLC acquired a new position in shares of Omeros in the fourth quarter valued at approximately $450,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Omeros by 4.2% in the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock valued at $3,480,000 after buying an additional 8,170 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.